National Institute of Neurological Disorders and Stroke Grants

Open National Institute of Neurological Disorders and Stroke grants

• Precision Editing of Granulin Mutations that Cause Frontotemporal Dementia

  Up to $6.6MDeadline: Jul 31, 2029open

  Frontotemporal dementia (FTD) is the most common form of presenile dementia before the age of 60, and no effective treatments are available. 40% of FT...

• Cilostazol for Prevention of Recurrent Stroke (CLARITY)

  Up to $5.7MDeadline: Jul 31, 2026open

  /ABSTRACT In recent years, clinical trials have demonstrated that ischemic stroke recurrence can be reduced during the first weeks after stroke or TIA...

• Investigating aberrant vesicular degradation and lipid metabolism in neurodegeneration

  Up to $3.3MDeadline: Jul 31, 2029open

  BOSCO/MASSI – ABSTRACT Profilin-1 (PFN1) is an actin-binding protein that is best known for its role in regulating cytoskeletal dynamics. In 2012, we ...

• Neural Repair for Chronic Incomplete Cervical Spinal Cord Injury with Nogo Receptor Blockade plus Rehabilitative Training

  Up to $3.3MDeadline: Nov 30, 2030open

  SUMMARY Traumatic spinal cord injury (SCI) affects approximately 300,000 individuals in the United States, leading to persistent neurological deficits...

• Characterization of Antigen-Specific Immune Response in ALS

  Up to $3.2MDeadline: Jul 31, 2029open

  Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that primarily affects motor neurons (MNs) in the brain and spinal cord. The ...

• Spatial organization and conformational ensembles of amyloids inside cells

  Up to $3.2MDeadline: Jul 31, 2029open

  The formation of intracellular inclusions containing fibrillar aggregates of alpha-synuclein (α-syn) is a hallmark of neurodegenerative diseases such ...

• Anxiety and depression in a nonhuman primate model of synucleinopathy

  Up to $3.1MDeadline: Jul 31, 2029open

  Intraneuronal inclusions of aggregated Synuclein (Syn), termed Lewy bodies (LBs), are a pathological hallmark of Parkinson’s disease (PD), PD dementia...

• SARS-CoV-2 initiation and acceleration of AD pathology in the setting of endogenous and exogenous risk factors

  Up to $3.0MDeadline: Jul 31, 2029open

  The uncertain etiology of Alzheimer’s disease poses significant obstacles to the development of both therapeutic and prevention strategies. At the roo...

• The role of a metazoan-specific PQC system in protecting against TDP-43 proteinopathies

  Up to $2.8MDeadline: Jul 31, 2029open

  The overall goal of this application is to elucidate the role of TRIM10 in maintaining solubility and function of TDP-43 and protecting against TDP-43...

• The relationship between ocus-coeruleus-norepinephrine network and neurovascular coupling in health and disease

  Up to $2.8MDeadline: Jul 31, 2029open

  The brain requires a continuous supply of nutrients and oxygen to fuel its normal functioning.

• Structure-function relationships in alpha-synuclein strain biology

  Up to $2.7MDeadline: Jul 31, 2029open

  Cryo-electron microscopy (cryo-EM) studies have shown that protein fibrils isolated from patient samples adopt distinct misfolded conformations, which...

• Impact of SARS-CoV-2 on the cerebrovasculature as a risk factor for VCID: Role of Wnt/beta-catenin

  Up to $2.5MDeadline: Jul 31, 2029open

  COVID-19 increases the risk of vascular contributions to cognitive impairment and dementia (VCID). VCID is one of the most prevalent forms of dementia...

• Promoting Engagement and Clinical Trial Readiness for Alzheimer's Disease and Related Dementias Among Underserved Sexual and Gender Minorities

  Up to $2.2MDeadline: Jul 31, 2029open

  SUMMARY Sexual and gender minorities (SGM), defined here as individuals who identify as lesbian, gay, bisexual, transgender, queer, intersex, asexual,...

• Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXT

  Up to $2.1MDeadline: Aug 14, 2026open

  The long-term objective of the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) initiative is to efficiently translate advances in ne...

• Development of MMP-9 inhibitory monoclonal antibodies to relieve neuropathic pain

  Up to $2.1MDeadline: Jul 31, 2027open

  Diabetic neuropathic pain affects millions of Americans but there continues to be an unmet need for safe and effective pain medications. Opioids and n...

• BRAIN CONNECTS: Light microscopy for cell-type specific mesoscale to nanoscale dense connectomics

  Up to $2.0MDeadline: May 31, 2028open

  In recent years, there has been remarkable progress in mapping the connectivity of cell types in the brain. We now have complete connectomes for insec...

• Targeting Inflammation-Resolution Pathways to Limit VCID

  Up to $2.0MDeadline: May 31, 2029open

  There are currently no effective therapies to reduce vascular contributions to cognitive impairment and dementia (VCID), which contribute to the overa...

• In Vivo Characterization of White Matter Hyperintensity Using Individualized Analysis of Multimodal Imaging

  Up to $1.9MDeadline: Apr 30, 2029open

  White matter hyperintensities (WMHs) are common findings in older adults, appearing as high-signal areas on T2-weighted MRI scans. While often linked ...

• FDA Phase 1 Development of a Novel Nonopioid Cell and Tissue Permeable Peptide Therapeutic for Epigenetic Reprogramming of Neuropathic Pain

  Up to $1.5MDeadline: Jul 31, 2027open

  Neuropathic pain (NeP) affects an estimated 7-10% of the population. In the most severe cases, pain can be disabling, severely affecting a patient’s q...

• Neuronal Activity-Induced IEG Transcription Factors in Neurodevelopment and Plasticity

  Up to $1.2MDeadline: May 31, 2033open

  Neural circuits are continually shaped and reshaped during development and throughout life in response to ongoing experience. In addition to short-te...

Where National Institute of Neurological Disorders and Stroke grants go

Recent grant recipients are concentrated in these states. Funders sometimes fund outside their primary states for high-fit projects, so don't self-eliminate solely on geography — check each opportunity's stated eligibility.

How to apply for National Institute of Neurological Disorders and Stroke grants

Most National Institute of Neurological Disorders and Stroke applications require: an organizational profile with mission and programs, a project proposal aligned with the funder's stated priorities, a project budget, and supporting attachments (IRS determination letter, board list, recent financials). Federal applicants additionally need a SAM.gov UEI and an active Grants.gov account.